Guselkumab Biosimilar - Research Grade

Human

IL-23

>1mg/ml

Human IgG1-Lambda3

Risankizumab Biosimilar - Research Grade (ICH5210), Tildrakizumab Biosimilar - Research Grade (ICH5303), Brazikumab Biosimilar - Research Grade (ICH5413), Mirikizumab Biosimilar - Research Grade (ICH5683), Picankibart Biosimilar - Research Grade (ICH5772)

https://www.imgt.org/mAb-DB/

ICH3002

Q9NPF7

51561

RRID:AB_2921606

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of guselkumab, supplied strictly for research use only. It is built around the same molecular target as the originator antibody, human interleukin-23 (specifically the p19 subunit, IL-23A; UniProt Q9NPF7), and is formatted as a human IgG1-lambda immunoglobulin. It is not the clinical drug and is not intended for human or veterinary use. The preparation is offered at research grade with low endotoxin (typically <1 EU/mg, with ultra-low <0.5 EU/mg options), and can be produced in bulk milligram-to-gram quantities to support scaled and repeated experiments. Because it recapitulates the target-binding behaviour of the reference molecule, it is useful as a well-defined tool reagent for in-vitro and preclinical investigation of IL-23 biology: isotype-matched binding studies, cytokine neutralisation assays, positive/reference controls in comparator panels, ligand-blockade experiments, and as a benchmark antibody in assay development. Its consistency and availability in bulk make it suitable for standardising workflows across labs and over time. Interleukin-23 (IL-23) is a heterodimeric, pro-inflammatory cytokine composed of a unique p19 subunit (IL-23A, encoded at UniProt Q9NPF7) covalently paired with the p40 subunit (IL12B) that it shares with IL-12. It is produced mainly by activated dendritic cells and macrophages. IL-23 signals through a receptor complex of IL-23R and IL-12RB1, driving JAK2/TYK2 and STAT3 activation. A central function is the survival, expansion, and terminal differentiation of T helper 17 (Th17) cells and other IL-17-producing populations, sustaining downstream release of IL-17, IL-22, and GM-CSF. This IL-23/Th17 axis is a key driver of chronic tissue inflammation and has been strongly implicated in psoriasis, psoriatic arthritis, and inflammatory bowel disease. Selective targeting of the p19 subunit blocks IL-23 while sparing IL-12, distinguishing it from p40-directed approaches.

IL-23 subunit alpha, IL-23-A, Interleukin-23 subunit p19, IL-23p19, Interleukin-23 subunit alpha, SGRF

Detects human IL23. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Guselkumab.

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

SIM0025

Guselkumab (anti-IL-23) Biosimilar

Q: Is the Guselkumab biosimilar available in gram quantities?

A: Yes — it is supplied in scalable milligram to gram quantities for heavy-usage and high-throughput laboratories.

Q: Is this research-grade Guselkumab suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Guselkumab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Guselkumab that binds human IL-23.